ISAR Research Updates

Define Responders and Non-Responders to Biologics and Describe Their Characteristics Overall and Per Biologic (BEAM)

Aims:
– To classify responders to biologic treatment by clinical and functional endpoints and describe their characteristics overall and per biologic drug class.
– To operationally assess response to biologic therapy by clinical and functional endpoints including exacerbations, systemic corticosteroids, asthma control and lung function.
– To describe and compare baseline (pre-therapy) demographic, clinical and functional characteristics of response and non-response groups to overall biologic treatment and by biologic class.

Describe the Clinical Outcome Before and After Biologic Treatment by Biologic Class, by Individual Biologic, and by Subgroups of Baseline Characteristics (LUMINANT)

Aims:
– To describe the proportions of patients by biologic class and drug.
– To describe clinical outcomes before and after biologic initiation.
– To describe clinical outcomes before and after biologic initiation for demographic/clinical subgroups (e.g. early/late age of onset, nasal polyps).

Impact of Co-Morbidity in Severe Asthma (PRISM)

Aims:
–  To illustrate the baseline prevalence, demographic and clinical characteristics of severe asthma patients with comorbidities.
–  To investigate the effects of comorbidity (e.g. sleep apnea, nasal polyps) on severe asthma clinical outcomes.

Comparative effectiveness across severe asthma biologic classes (Anti-IL5 vs Anti lgE) in patients eligible for both modalities (FIRE)

Aims:
– To describe severe asthma patients eligible for both Anti-IL5 and Anti-IgE.
– To describe and compare clinical outcomes of patients receiving Anti-IL5 or Anti-IgE versus those maintained on OCS in terms of asthma control, exacerbations, lung function.

Read More